Evidence map›Paper›PMID 26294292›Full record

ArticleOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2016

Elevated incidence of fractures in women with invasive breast cancer.

B J Edwards, W J Gradishar, M E Smith, J A Pacheco, J Holbrook, J M McKoy, B Nardone, S Tica, V Godinez-Puig, A W Rademaker and 6 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 24 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 1 country.

B J EdwardsDepartment of General Internal Medicine, University of Texas, MD Anderson Cancer Center, 1515 Holcombe, unit 1465, Houston, TX, 77030, USA. bedwards@mdanderson.org.
W J GradisharRobert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA.
M E SmithNUgene Project, Center for Genetic Medicine, Northwestern University, Chicago, IL, USA.
J A PachecoNUgene Project, Center for Genetic Medicine, Northwestern University, Chicago, IL, USA.
J HolbrookDepartment of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
J M McKoyRobert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA.
B NardoneDepartment of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
S TicaDepartment of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
V Godinez-PuigDepartment of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
A W RademakerDepartment of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
I B HelenowskiDepartment of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
A D BuntaDepartment of Orthopaedic Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
P H SternDepartment of Molecular Pharmacology and Biological Chemistry, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
S T RosenRobert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA.
D P WestRobert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA.
T A GuiseDepartment of Medicine, Division of Endocrinology, Indiana University, Indianapolis, IN, USA.
Northwestern University · USIndiana University – Purdue University Indianapolis · USIndo-American Center · USRobert H. Lurie Comprehensive Cancer Center of Northwestern UniversityThe University of Texas MD Anderson Cancer Center · US

Funding

Research on Adverse Drug Events and Reports: Novel Multiple Myeloma DrugsR01CA125077 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI WEST, DENNIS PAUL · 2007 to 2009
$1.7M
Adverse Drug Reactions in Geriatric Cancer PatientsK01CA134554 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI MCKOY, JUNE M. · 2008 to 2012
$737k
NCI NIH HHS 3R01CA125077-03S1NCI NIH HHS 5 K01 CA134554-05PHS HHS 5R01-A125077-03
6 · The paper itself

Abstract

unlabelledThis study evaluates the incidence of bone fractures in women with BC.We found that women with invasive breast cancer are at an increased risk for bone fractures, with fractures most commonly occurring at lower extremity and vertebral sites. The risk is further increased in women undergoing cancer therapy.

introductionBone loss and fractures in breast cancer have generally been attributed to aromatase inhibitor use. This study assessed the incidence of fractures after invasive breast cancer diagnosis and evaluated bone density and FRAX risk calculation at time of fracture occurrence.

methodsRetrospective cohort study of women with invasive breast cancer [June 2003-December 2011] who participated in an academic hospital based genetic biobank. Demographic and clinical characteristics were abstracted from the electronic medical record (EMR).

resultsA total of 422 women with invasive breast cancer were assessed; 79 (28 %) sustained fractures during the observation period; fractures occurred at multiple skeletal sites in 27 cases (116 fractures). The incidence of fractures was 40 per 1000 person-years. Women who sustained fractures were mostly white and had a family history of osteoporosis (36.9 %, p = 0.03) or history of a prior fracture (6/79, p = 0.004). Fractures occurred 4.0 years (range 0-12 years) after cancer diagnosis. Fracture cases had femoral neck bone mineral density (BMD) of 0.72 + 0.12 g/cm(2), T-score of -1.2, that is, within the low bone mass range. Fractures most commonly occurred in lower extremities, vertebral, and wrist sites. Hip fractures accounted for 11 % of fractures, occurring at a median age of 61 years.

conclusionsFractures occur shortly after commencing cancer therapy. Rapid bone loss associated with cancer therapy may precipitate fractures. Fractures occur at relatively higher BMD in BC. Occurrence of fractures in invasive breast cancer raises the possibility of cancer-induced impairment in bone quality.

Indexed as

Absorptiometry, PhotonAdultAgedAged, 80 and overAntineoplastic AgentsBone DensityBreast NeoplasmsFemaleHumansIllinoisIncidenceMiddle AgedNeoplasm InvasivenessOsteoporosisOsteoporotic FracturesRetrospective StudiesAntineoplastic AgentsBreast cancerDisabilityFracturesFunctional statusMorbidityWomen’s health

Identifiers

PMID26294292
OpenAlexW2214791105

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.